Compare Repligen Corporation Common Stock (RGEN) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Schlumberger NV — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Schlumberger NV trades at $48.74 (market cap $72.38B). The key difference: Schlumberger NV is far larger — about 6.5× Repligen Corporation Common Stock's market cap, and Schlumberger NV pays a 2.42% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Schlumberger NV for 99 Days on average.
| RGEN | SLB | |
|---|---|---|
Market Cap | $11.14B | $72.38B |
Volume | 1,259,263 | 10,231,115 |
Sector | Health | Energy |
52-Week High | $194.57 | $60.10 |
52-Week Low | $102.87 | $32.57 |
Typical Hold Time | 0 Days | 99 Days |
Enterprise Value | $11.02B | $81.11B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SLB trades at $48.51, down 0.53% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with 8.53% net income margin and 13.37% ROE, though revenue declined slightly to $35.71B in 2025. Recent contract wins in Saudi Arabia, Oman, and Mozambique provide multi-year revenue visibility. Analyst consensus remains strongly bullish with 85% buy ratings and $64.58 price target representing 33% upside potential.
SLB presents a compelling value opportunity with solid fundamentals and strong analyst support, though near-term headwinds include declining profit margins and bearish technical indicators. The company's recent major contract awards and dividend payments provide stability, but investors should monitor execution risks in international markets and potential volatility in energy sector demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
